Combined Phase I-Phase II Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs Descartes 08 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Cartesian Therapeutics
- 03 Jun 2019 Planned End Date changed from 1 Mar 2020 to 1 Sep 2020.
- 03 Jun 2019 Planned number of patients changed from 15 to 30.
- 03 Jun 2019 Planned primary completion date changed from 26 Feb 2019 to 26 Feb 2020.